Physicians' Academy for Cardiovascular Education

Familial Hypercholesterolemia

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Tools to detect FH

10' education - June 23, 2020 - Rens Reeskamp, MD

Familial hypercholesterolemia in children and adolescents

10' education - June 2, 2020 - Bert Wiegman, MD, PhD

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?

5' education - Oct. 23, 2019 - Paris, France - Prof. François Mach, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CME

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

A minority of FH patients is identified and labeled as such, which impacts treatment

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)
##SCROLLER_ITEMS_FULL_TITLE##

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands
##SCROLLER_ITEMS_FULL_TITLE##

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
##SCROLLER_ITEMS_FULL_TITLE##

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
##SCROLLER_ITEMS_FULL_TITLE##

Lipid Management 2020: A glance at the future

10' education - Sep. 24, 2015
##SCROLLER_ITEMS_FULL_TITLE##

A new prediction tool to identify disease-causing mutations in familial hypercholesterolaemia

3' education - May 24, 2015 - ISA2015, Amsterdam - Joost Besseling
##SCROLLER_ITEMS_FULL_TITLE##

FH: Call for investigators to get involved

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Evan Stein
##SCROLLER_ITEMS_FULL_TITLE##

Homozygous FH: treatment challenges

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
##SCROLLER_ITEMS_FULL_TITLE##

PCSK9-inhibitor less frequently administered may be effective treatment option

3' education - June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
##SCROLLER_ITEMS_FULL_TITLE##

TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients

3' education - June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
##SCROLLER_ITEMS_FULL_TITLE##

Screening for Familial Hypercholesterolaemia

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - dr. Kees Hovingh
##SCROLLER_ITEMS_FULL_TITLE##

Strong reduction CV events in FH patients with ApoB-inhibitor

3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Paul Barton Duell

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD
Nick Nurmohamed explains what Lp(a) is and how correction of LDL-c for Lp(a) reduces genetic testing for FH.

Nick Nurmohamed explains what Lp(a) is and how correction of LDL-c for Lp(a) reduces genetic testing for FH.

Higher frequency of coronary atherosclerotic plaques in patients with genetically confirmed FH

Literature - July 7, 2020 - Pang J et al., - Atherosclerosis. 2020.

Among asymptomatic phenotypic FH patients, patients with a genetically confirmed FH diagnosis had a higher frequency and severity of coronary atherosclerotic plaques, compared to those without a FH-causing mutation.

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD
In this video internist Kees Hovingh discusses why screening for FH is important and tools used for its diagnosis.

In this video, internist Kees Hovingh discusses why screening for FH is important and how to identify individual FH patients and their families. With question to test your knowledge.

Incorporation of genetic testing increases rates of diagnosis for FH

Literature - June 29, 2020 - Brown EE et al., - J Clin Lipidol. 2020.

This study showed that incorporation of genetic testing results in increased numbers of patients diagnosed with definite FH, compared to classification based solely on clinical criteria.

Tools to detect FH

10' education - June 23, 2020 - Rens Reeskamp, MD
Rens Reeskamp discusses diagnostic tools of FH that may increase the chance of finding patients with an FH-causing mutation.

Rens Reeskamp discusses tools that may help to increase the chance of finding FH patients. With question to test your knowledge.

Phase 2 dose-finding study with PCSK9i in children and adolescents with HeFH

Literature - June 18, 2020 - Daniels S et al., - J Clin Lipidol. 2020.

This phase 2 study with alirocumab decreased LDL-c levels and was generally well tolerated in pediatric HeFH patients. Two dosing regimens were selected for further investigation in a phase 3 trial.

Statin therapy effective and safe in children and adolescents with FH

Literature - June 15, 2020 - Anagnostis P et al., - Endocrine 2020.

Statins lowered total cholesterol, LDL-c, triglycerides and apo-B levels and increased HDL-c levels in children and adolescents with FH, as shown in this systematic review and meta-analysis.

Higher FH prevalence in IHD and severe hypercholesterolemia subpopulations

Literature - June 2, 2020 - Beheshti SO et al., - J Am Coll Cardiol 2020.

Compared to worldwide FH prevalence in the general population, FH prevalence is higher in subpopulations of subjects with IHD and severe hypercholesterolemia, as demonstrated by meta-analyses.

Familial hypercholesterolemia in children and adolescents

10' education - June 2, 2020 - Bert Wiegman, MD, PhD
Pediatric cardiologist Bert Wiegman discusses the need for early detection and treatment of children with familial hypercholesterolemia

Pediatric cardiologist Bert Wiegman discusses the need for early detection and treatment of children with familial hypercholesterolemia. With question to test your knowledge.

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD
Dirk Blom discusses the design and outcomes in the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

ACC 2020 Dirk Blom discusses the design and outcomes of the ODYSSEY HoFH trial, evaluating LDL-c lowering and safety of alirocumab in HoFH patients.

Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020
An antibody against angiopoietin-like protein 3 (ANGPTL3) resulted in lowering of LDL-c in homozygous FH patients, independent of LDL receptor function.

ACC 2020 An antibody against angiopoietin-like protein 3 (ANGPTL3) resulted in lowering of LDL-c in homozygous FH patients, independent of LDL receptor function.

PCSK9 inhibitor reduces LDL-c in patients with HoFH

News - Apr. 1, 2020

ACC 2020 The ODYSSEY HoFH trial demonstrated that treatment with alirocumab reduced LDL-c in HoFH patients compared to placebo, and alirocumab was found to be well tolerated and safe.